多中心前瞻性观察研究:立体定向放射外科治疗多发性脑转移瘤(JLGK0901研究更新)——照射相关并发症与简易精神状态检查评分的长期维持
JLGK0901研究更新显示,对1-10个新诊断脑转移瘤患者行伽玛刀SRS后,5-10个(C组)与2-4个(B组)及1个(A组)在MMSE评分维持率和SRS相关并发症累积发生率上均无显著差异,长期随访进一步支持SRS单独治疗5-10个脑转移瘤非劣于2-4个。
要点
- 5-10个脑转移瘤SRS后48个月MMSE维持率89%,与2-4个(86%)和1个(87%)无显著差异。
- SRS相关并发症48个月累积发生率三组分别为12%、12%、13%,组间无显著差异。
- 白质脑病仅见于1.1%随访MRI患者,其中11/12发生于挽救性全脑放疗后。
核心结论
- SRS单独治疗5-10个脑转移瘤患者,其MMSE评分维持和SRS相关并发症发生率与2-4个及1个脑转移瘤患者无显著差异,长期随访支持其非劣效性。
研究设计与样本
- 多中心前瞻性观察研究,纳入23家机构2009年3月1日至2012年2月15日接受伽玛刀SRS的1-10个新诊断脑转移瘤患者,共1194例可评估,分为A组(1个,n=455)、B组(2-4个,n=531)、C组(5-10个,n=208)。
主要发现
- A、B、C组48个月MMSE维持率分别为87%、86%、89%,A vs B的HR=0.719(95%CI 0.437-1.172,P=.18),B vs C的HR=1.280(95%CI 0.696-2.508,P=.43)。
- 中位观察12.0个月(范围0.3-67.5个月),145例(12.1%)发生SRS相关并发症;48个月累积发生率A、B、C组分别为12%、12%、13%,A vs B的HR=0.850(95%CI 0.592-1.220,P=.38),B vs C的HR=1.052(95%CI 0.666-1.662,P=.83)。
- 1074例有随访MRI的患者中12例(1.1%)发生白质脑病,其中11例在挽救性全脑放疗后检出,检出时间为全脑放疗后5.2至21.2个月(中位11.0个月,IQR 7.0-14.4个月)。
临床怎么用
- 对于5-10个新诊断脑转移瘤患者,可考虑单独SRS作为初始治疗,长期随访未显示认知功能维持或并发症劣于2-4个脑转移瘤患者。
- SRS后需关注挽救性全脑放疗后白质脑病的发生风险,尤其在多发性脑转移瘤患者中。
局限性
- 观察期虽延长但部分患者随访时间仍有限,中位观察仅12.0个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The JLGK0901 study showed the noninferiority of stereotactic radiosurgery (SRS) alone as initial treatment of 5 to 10 brain metastases (BMs) compared with 2 to 4 BMs in terms of overall survival and most secondary endpoints (Lancet Oncol 2014;15:387-95). However, observation periods were not long enough to allow confirmation of the long-term safety of SRS alone in patients with 5 to 10 BMs. METHODS AND MATERIALS: This was a prospective observational study of Gamma Knife SRS-treated patients with 1 to 10 newly diagnosed BMs enrolled at 23 facilities between March 1, 2009, and February 15, 2012. RESULTS: The 1194 eligible patients were categorized into the following groups: group A, 1 tumor (n=455); group B, 2 to 4 tumors (n=531); and group C, 5 to 10 tumors (n=208). Cumulative rates of Mini-Mental State Examination (MMSE) score maintenance (MMSE score decrease <3 from baseline) determined with a competing risk analysis of groups A, B, and C were 93%, 91%, and 92%, respectively, at the 12th month after SRS; 91%, 89%, and 91%, respectively, at the 24th month; 89%, 88%, and 89%, respectively, at the 36th month; and 87%, 86%, and 89%, respectively, at the 48th month (hazard ratio [HR] of group A vs group B, 0.719; 95% confidence interval [CI], 0.437-1.172; P=.18; HR of group B vs group C, 1.280; 95% CI, 0.696-2.508; P=.43). During observations ranging from 0.3 to 67.5 months (median, 12.0 months; interquartile range, 5.8-26.5 months), as of December 2014, 145 patients (12.1%) had SRS-induced complications. Cumulative complication incidences by competing risk analysis for groups A, B, and C were 7%, 8%, and 6%, respectively, at the 12th month after SRS; 10%, 11%, and 11%, respectively, at the 24th month; 11%, 11%, and 12%, respectively, at the 36th month; and 12%, 12%, and 13%, respectively, at the 48th month (HR of group A vs group B, 0.850; 95% CI, 0.592-1.220; P=.38; HR of group B vs group C, 1.052; 95% CI, 0.666-1.662, P=.83). Leukoencephalopathy occurred in 12 of the 1074 patients (1.1%) with follow-up magnetic resonance imaging and was detected after salvage whole-brain radiation therapy in 11 of these 12 patients. In these 11 patients, leukoencephalopathy was detected by magnetic resonance imaging 5.2 to 21.2 months (median, 11.0 months; interquartile range, 7.0-14.4 months) after whole-brain radiation therapy. CONCLUSIONS: Neither MMSE score maintenance nor post-SRS complication incidence differed among groups A, B, and C. This longer-term follow-up study further supports the already-reported noninferiority hypothesis of SRS alone for patients with 5 to 10 BMs versus 2 to 4 BMs.
引用
- Yamamoto M, Serizawa T, Higuchi Y, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816158. doi:10.1016/j.ijrobp.2017.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。